0001802806-23-000013.txt : 20231215 0001802806-23-000013.hdr.sgml : 20231215 20231215164904 ACCESSION NUMBER: 0001802806-23-000013 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20231215 DATE AS OF CHANGE: 20231215 EFFECTIVENESS DATE: 20231215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KAZIA THERAPEUTICS LTD CENTRAL INDEX KEY: 0001075880 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-499912 FILM NUMBER: 231491058 BUSINESS ADDRESS: STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24, STREET 2: 300 BARANGAROO AVENUE CITY: SYDNEY NSW STATE: C3 ZIP: 2000 BUSINESS PHONE: 01161298780088 MAIL ADDRESS: STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24, STREET 2: 300 BARANGAROO AVENUE CITY: SYDNEY NSW STATE: C3 ZIP: 2000 FORMER COMPANY: FORMER CONFORMED NAME: NOVOGEN LTD DATE OF NAME CHANGE: 19981228 D 1 primary_doc.xml X0708 D LIVE 0001075880 KAZIA THERAPEUTICS LTD THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 AUSTRALIA 2000 01161298780088 AUSTRALIA NOVOGEN LTD Corporation true John Friend THREE INTERNATIONAL TOWERS LEVEL 24 300 BARANGAROO AVENUE SYNDEY NSW C3 AUSTRALIA 2000 Executive Officer Director Karen Krumeich THREE INTERNATIONAL TOWERS LEVEL 24 300 BARANGAROO AVENUE SYNDEY NSW C3 AUSTRALIA 2000 Executive Officer Bryce Carmine THREE INTERNATIONAL TOWERS LEVEL 24 300 BARANGAROO AVENUE SYNDEY NSW C3 AUSTRALIA 2000 Director Steven Coffey THREE INTERNATIONAL TOWERS LEVEL 24 300 BARANGAROO AVENUE SYNDEY NSW C3 AUSTRALIA 2000 Director Ebru Davidson THREE INTERNATIONAL TOWERS LEVEL 24 300 BARANGAROO AVENUE SYNDEY NSW C3 AUSTRALIA 2000 Director Biotechnology Decline to Disclose 06b false 2023-12-05 false true true false 0 H.C.WAINWRIGHT & CO., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK false 2000000 2000000 0 false 1 0 true 0 In connection with the registered direct offering concurrent with this private placement, the placement agent received warrants to purchase up to 311,111 American Depoistary Shares ("ADSs") exercisable at $0.5625 per ADS. 0 false KAZIA THERAPEUTICS LTD /s/ Karen Krumeich Karen Krumeich CFO 2023-12-15